# A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

> **NCT03846310** · PHASE1 · COMPLETED · sponsor: **Arcus Biosciences, Inc.** · enrollment: 77 (actual)

## Conditions studied

- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Nonsquamous Nonsmall Cell Neoplasm of Lung
- Sensitizing EGFR Gene Mutation

## Interventions

- **DRUG:** Etrumadenant
- **DRUG:** Zimberelimab
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03846310
- **Lead sponsor:** Arcus Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-01
- **Primary completion:** 2024-11-18
- **Final completion:** 2024-11-18
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2024-12-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03846310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03846310, "A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03846310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*